Merck KGaA Plays Down Mavenclad Label And $99,500 annual Price For 10 MS Pills

 
• By Sten Stovall
  
Brain
FDA Approved Merck Group's oral Mavenclad in RRMS and active SPMS. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip